Literature DB >> 15164821

Quantitative electroencephalography in frontotemporal dementia with methylphenidate response: a case study.

Harold W Goforth1, Lukasz Konopka, Margaret Primeau, Amity Ruth, Kathleen O'Donnell, Roopal Patel, Teresa Poprawski, Parvez Shirazi, Murali Rao.   

Abstract

Frontotemporal dementia is an underdiagnosed illness with predominant behavioral and executive manifestations. Historically, diagnosis has been based on a combination of clinical history, neuropsychological testing, and brain imaging. No effective treatment currently exists for this disorder. A case is presented using quantitative EEG with methylphenidate challenge correlated with SPECT. The patient underwent neuropsychological testing, a SPECT brain study, and a quantitative EEG, which was repeated after methylphenidate administration. SPECT was significant for hypoperfusion to the bilateral frontotemporal regions, with left-sided hypoperfusion greater than homologous right as demonstrated by LORETA analysis. QEEG correlated with SPECT, and demonstrated profound left greater than right bi-frontotemporal slowing, which normalized partially after methylphenidate administration. The patient has remained on methylphenidate as an outpatient, and has had significant behavioral improvement. Quantitative EEG may provide both diagnostic and therapeutic data with regard to frontotemporal dementia. Further studies of methylphenidate in this population are needed to confirm these data.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15164821     DOI: 10.1177/155005940403500212

Source DB:  PubMed          Journal:  Clin EEG Neurosci        ISSN: 1550-0594            Impact factor:   1.843


  14 in total

1.  Neuropsychiatric symptoms in primary progressive aphasia: phenomenology, pathophysiology, and approach to assessment and treatment.

Authors:  Mandana Modirrousta; Bruce H Price; Bradford C Dickerson
Journal:  Neurodegener Dis Manag       Date:  2013-04-01

Review 2.  Use of Stimulants in Bipolar Disorder.

Authors:  Giulio Perugi; Giulia Vannucchi; Fulvio Bedani; Ettore Favaretto
Journal:  Curr Psychiatry Rep       Date:  2017-01       Impact factor: 5.285

Review 3.  Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia.

Authors:  Geoffrey A Kerchner; Maria Carmela Tartaglia; Adam Boxer
Journal:  Expert Rev Neurother       Date:  2011-05       Impact factor: 4.618

Review 4.  Medical management of frontotemporal dementias: the importance of the caregiver in symptom assessment and guidance of treatment strategies.

Authors:  Gregory A Jicha
Journal:  J Mol Neurosci       Date:  2011-06-07       Impact factor: 3.444

5.  Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options.

Authors:  Gregory A Jicha; Peter T Nelson
Journal:  Neurodegener Dis Manag       Date:  2011-04

6.  FTLD Treatment: Current Practice and Future Possibilities.

Authors:  Peter A Ljubenkov; Adam L Boxer
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia.

Authors:  Edward D Huey; Karen T Putnam; Jordan Grafman
Journal:  Neurology       Date:  2006-01-10       Impact factor: 9.910

Review 8.  Attention-deficit/hyperactivity disorder in older adults: prevalence and possible connections to mild cognitive impairment.

Authors:  Nikki Ivanchak; Kristen Fletcher; Gregory A Jicha
Journal:  Curr Psychiatry Rep       Date:  2012-10       Impact factor: 5.285

Review 9.  Pharmacotherapy for Frontotemporal Dementia.

Authors:  Rita Khoury; Yu Liu; Quratulanne Sheheryar; George T Grossberg
Journal:  CNS Drugs       Date:  2021-04-11       Impact factor: 5.749

10.  Frontotemporal dementias: a review.

Authors:  Natalie D Weder; Rehan Aziz; Kirsten Wilkins; Rajesh R Tampi
Journal:  Ann Gen Psychiatry       Date:  2007-06-12       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.